Sepracor reduces stake in BioSphere Medical:
This article was originally published in Clinica
BioSphere Medical, a Nasdaq-quoted US company which is developing embolotherapy and non-embolotherapy applications for its proprietary bioengineered acrylic beads, is to offer four million shares at $11 a share. Two million come from pharmaceuticals manufacturer Sepracor, which presently owns more than 50% of BioSphere. Sepracor has seen its own share price fall from $138.25 to less than $38 in the past 52 weeks.